OR WAIT 15 SECS
Quotient Clinical has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor Spray Dryer.
Quotient Clinical, the Translational Pharmaceutics Company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor Spray Dryer, according to an April 12, 2016 press announcement. Quotient develops spray-dried dispersions to overcome drug compound solubility issues, and the addition of a larger-scale spray dryer will allow the production of a range of batch sizes, up to two kilograms.
Located at Quotient’s new GMP facility at MediCity in Nottingham, UK-which is scheduled to open later in 2016-this expansion is a direct response to customer requests for ongoing product development support, including toxicology and later-stage clinical studies, Quotient said in a press announcement.
“Poor solubility is increasingly prevalent in drug pipelines across the industry,” said Nikki Whitfield, vice-president of Pharmaceutical Sciences. “We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to address these complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimized formulations to support our clients’ downstream clinical development programs.”
Source: Quotient Clinical